Blog

Ibrahim Halil Sahin: I discussed the findings of neoadjuvant rectal cancer study of Dostarlimab with Alison Kanski

Photo collage of Ibrahim Halil Sahin and Alison Kanski taken from X

Jun 10, 2024, 04:49

Ibrahim Halil Sahin: I discussed the findings of neoadjuvant rectal cancer study of Dostarlimab with Alison Kanski

Ibrahim Halil Sahin Assistant Professor of Medicine Division of Hematology/Oncology at University of Pittsburgh School of Medicine, shared a post on X:

“I discussed the findings of neoadjuvant rectal cancer study of Dostarlimab with Alison Kanski Precision Oncology News!

Immunotherapy has revolutionized the management of patients with MSI-H CRC and will continue to do so!”

Ibrahim Halil Sahin

Source: Ibrahim Halil Sahin/X

Alison Kanski cancer Cancer Management cancer treatment colorectal cancer Dostarlimab Hematology Oncology Ibrahim Halil Sahin immunotherapy innovative cancer therapies Medical Advancements MSI-H CRC neoadjuvant rectal cancer study OncoDaily Oncology oncology discussion oncology research Precision Medicine Precision Oncology News Research University of Pittsburgh School of Medicine

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage